NCT07150104 · OUTCOME
DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM · Source last updated 2026-06-25
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure COUNT_OF_PARTICIPANTS
Unit Participants
Interval / dispersion Not reported
Time frame Baseline (Day 1) and up to 137 weeks What was measured Blood samples were collected for the analysis of chemistry parameters. The laboratory parameters were graded according to CTCAE version 5. G1: mild; G2: moderate; G3: severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2, G3, and G4 are presented. Baseline value was defined as the most recent, non-missing value from a local laboratory prior to the first dose of study treatment. CPK = creatine kinase.
Analysis population: Safety population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified categories.
Groups in this outcome 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 0.5 mg/kg belantamab mafodotin intravenous (IV) infusion as powder for solution once every 4 weeks (Q4W) infused over 30- 60 minutes on day 1 of each 28-day cycle in combination with 100 mg Nirogacestat administered orally twice a day (BID) up to Day 28. Along with 4 mg Pomalidomide orally per day (QD) on Days 1-21 of each 28-day cycle and Dexamethasone 40mg (20 mg for participants \>75 years old or BMI \<18.5 kg/m\^2) administered orally on days 1, 8, 15 and 22 of each 28-day cycle.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Reported measurements Hypoglycemia, Increase to Grade 1 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 4 Not reported Not reported Not reported Not reported
Hypoglycemia, Increase to Grade 2 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypoglycemia, Increase to Grade 3 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypoglycemia, Increase to Grade 4 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypoalbuminemia, Increase to Grade 1 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 4 Not reported Not reported Not reported Not reported
Hypoalbuminemia, Increase to Grade 2 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 4 Not reported Not reported Not reported Not reported
Hypoalbuminemia, Increase to Grade 3 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypoalbuminemia, Increase to Grade 4 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
CPK increased, Increase to Grade 1 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 2 Not reported Not reported Not reported Not reported
CPK increased, Increase to Grade 2 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 3 Not reported Not reported Not reported Not reported
CPK increased, Increase to Grade 3 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
CPK increased, Increase to Grade 4 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hyperkalemia, Increase to Grade 1 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 2 Not reported Not reported Not reported Not reported
Hyperkalemia, Increase to Grade 2 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 1 Not reported Not reported Not reported Not reported
Hyperkalemia, Increase to Grade 3 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hyperkalemia, Increase to Grade 4 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Blood lactate dehydrogenase increased, Increase to Grade 1 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 10 Not reported Not reported Not reported Not reported
Blood lactate dehydrogenase increased, Increase to Grade 2 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Blood lactate dehydrogenase increased, Increase to Grade 3 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Blood lactate dehydrogenase increased, Increase to Grade 4 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypermagnesemia, Increase to Grade 1 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 2 Not reported Not reported Not reported Not reported
Hypermagnesemia, Increase to Grade 2 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypermagnesemia, Increase to Grade 3 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypermagnesemia, Increase to Grade 4 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypomagnesemia, Increase to Grade 1 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 4 Not reported Not reported Not reported Not reported
Hypomagnesemia, Increase to Grade 2 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypomagnesemia, Increase to Grade 3 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypomagnesemia, Increase to Grade 4 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypernatremia, Increase to Grade 1 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 2 Not reported Not reported Not reported Not reported
Hypernatremia, Increase to Grade 2 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypernatremia, Increase to Grade 3 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypernatremia, Increase to Grade 4 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypercalcemia, Increase to Grade 1 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 1 Not reported Not reported Not reported Not reported
Hypercalcemia, Increase to Grade 2 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 1 Not reported Not reported Not reported Not reported
Hypercalcemia, Increase to Grade 3 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypercalcemia, Increase to Grade 4 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Hypocalcemia, Increase to Grade 1 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 2 Not reported Not reported Not reported Not reported
Hypocalcemia, Increase to Grade 2 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 1 Not reported Not reported Not reported Not reported
Hypocalcemia, Increase to Grade 3 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 1 Not reported Not reported Not reported Not reported
Hypocalcemia, Increase to Grade 4 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 14
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Chronic Kidney Disease, Increase to Grade 1 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 11
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 0 Not reported Not reported Not reported Not reported
Chronic Kidney Disease, Increase to Grade 2 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 11
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 3 Not reported Not reported Not reported Not reported
Chronic Kidney Disease, Increase to Grade 3 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 11
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 1 Not reported Not reported Not reported Not reported
Chronic Kidney Disease, Increase to Grade 4 Analysis denominator · Participants
Group Source count 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 11
Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone 1 Not reported Not reported Not reported Not reported
Complete source fields classes
title Hypoglycemia, Increase to Grade 1
title Hypoglycemia, Increase to Grade 2
title Hypoglycemia, Increase to Grade 3
title Hypoglycemia, Increase to Grade 4
title Hypoalbuminemia, Increase to Grade 1
title Hypoalbuminemia, Increase to Grade 2
title Hypoalbuminemia, Increase to Grade 3
title Hypoalbuminemia, Increase to Grade 4
title CPK increased, Increase to Grade 1
title CPK increased, Increase to Grade 2
title CPK increased, Increase to Grade 3
title CPK increased, Increase to Grade 4 Show more (12 of 44)
description Blood samples were collected for the analysis of chemistry parameters. The laboratory parameters were graded according to CTCAE version 5. G1: mild; G2: moderate; G3: severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2, G3, and G4 are presented. Baseline value was defined as the most recent, non-missing value from a local laboratory prior to the first dose of study treatment. CPK = creatine kinase. groups
description Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 0.5 mg/kg belantamab mafodotin intravenous (IV) infusion as powder for solution once every 4 weeks (Q4W) infused over 30- 60 minutes on day 1 of each 28-day cycle in combination with 100 mg Nirogacestat administered orally twice a day (BID) up to Day 28. Along with 4 mg Pomalidomide orally per day (QD) on Days 1-21 of each 28-day cycle and Dexamethasone 40mg (20 mg for participants \>75 years old or BMI \<18.5 kg/m\^2) administered orally on days 1, 8, 15 and 22 of each 28-day cycle.
id OG000
title 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone
param Type COUNT_OF_PARTICIPANTS
population Description Safety population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified categories.
reporting Status POSTED
time Frame Baseline (Day 1) and up to 137 weeks
title DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline
type PRIMARY
unit Of Measure Participants Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle